A recent US Supreme Court ruling found that companies cannot patent things found in nature. Peter Day asks what this means for the biotech business.
Ever since the mapping of the human genome was completed 10 years ago medical companies have been rushing to patent genes that define all of us for their own exclusive use. Now the US Supreme Court has ruled against patenting things found in nature. Peter Day asks what this means for the biotech business.and for the future of healthcare.
Contributors to this programme
Professor Sir John Burn
Professor of Clinical Genetics, Institute of Genetic Medicine Newcastle University
Author, Who Owns You?
Life Science Lawyer, Lawford Davies Denoon
Dr Michael Hopkins
Senior Lecturer, University of Sussex
Dr Berwyn Clarke
Dr Hani Gabra
Professor of Medical Oncology, Imperial College London
Dr Helen Wallace
Director Genewatch UK
Dr Stuart Hogarth
Research Fellow, Kings College London